Linda Stocum

Amy Paller, MD, sits down to answer important questions on the FDA approval of dupilumab for patients aged 6 months to 5 years.

Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis.

Kenneth J. Tomecki, MD, discussed the clinical relevance of sexually transmitted diseases to dermatology and outlined what to look for and how to treat various conditions at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.

Teenagers were the most likely to be affected by targeted misinformation.

Allergic contact dermatitis and atopic dermatitis are common causes of rashes in the pediatric population. Patch testing can help demystify the cause of such skin conditions and determine treatment.

The American Academy of Dermatology’s survey finds more Americans say sun protection is more important than 5 years ago, but don’t understand how to protect themselves.

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

What is the relationship between mental disorders and atopic dermatitis? Investigators from a recent study endeavored to find out.

An article in examines if any changes have been made to the diversity of dermatologic clinical trials conducted from 2010 to 2015 compared to 2015 to 2020.

A letter to the editor in the Journal of the American Academy of Dermatology investigated how mental health and its association to race and ethnicity relate to patients with acne.

Impetigo is a common skin infection in which ozenoxacin may be used as a treatment. A study aimed to evaluate the safety and efficacy of the therapy in pediatric patients compared to other topical treatments.

Research aimed to understand how using daily skin care such as a mild cleanser and moisturizer impacts skin health.

An interview with Adelaide Hebert, MD, how environmental factors may play a role in flare ups.

A study investigated the role diet habits have in the development, duration, and severity of acne.

The US Food and Drug Administration (FDA) has announced steps at improving the quality, safety, and efficacy of sunscreens.

Regeneron Pharmaceuticals, Inc. and Sanofi announced safety and efficacy results from LIBERTY AD trial for pediatric patients ages 6 months to 5 years.

A study published in the Journal of the American Academy of Dermatology examined the potential relationship between air pollution and the incidence of atopic dermatitis.

MediWound Ltd, announced the results for its CIDS trial studying NexoBrid as a treatment for children with severe thermal burns.

Dalbavancin has received US Food and Drug Administration (FDA) approval to treat acute bacterial skin and skin structure infections in pediatric patients.

A study examined the difference in prescribing patterns between pediatricians and dermatologists when it came to acne treatments.